![]() |
产地 | 中国 |
品牌 | Chemstan |
货号 | CSD00317 |
保存条件 | store at -80℃ |
用途 | 仅用于科研用途 |
应用范围 | |
抗原来源 | CHO cells |
CAS编号 | 1362509-93-0 |
保质期 | |
抗体名 | Idarucizumab ( 艾达赛珠单抗 ) |
是否单克隆 | |
克隆性 | |
靶点 | dabigatran etexilate mesylate[Drug] |
适应物种 | |
形态 | |
宿主 | |
标记物 | |
包装规格 | 100μg |
纯度 | % |
亚型 | |
标识物 | |
浓度 | 95% |
免疫原 | |
是否进口 | 否 |
货号(Catalog No.)
CSD00317
通用名INN
Idarucizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc).Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of dabigatran.Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199.
别名(Alternative names)
aDabi-Fab,anti-dabigatran,antidote for dabigatran
靶点;物种(Specificity target name;species)
dabigatran etexilate mesylate[Drug]
活性研究(体外/体内研究)(Activity in vitro)
Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC50: 10 nM), while showing no inhibitory effect on other platelet-stimulating agents. Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC50: 0.56 μM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 μM, respectively.
种类(Species)
Humanized
受体鉴定(Receptor identification)
Fab
化学信息
CAS
1362509-93-0
存储条件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .